Floatz logo

Decitabine

Acute Myeloid Leukemia With T(8;21)(Q22;Q22) Translocation

BGI, ChinaSmall moleculePhase 3Active
BB
70/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
60/ 100
Competitive Position
89/ 100

Competitive context

14 Active assets in the Acute Myeloid Leukemia With T(8;21)(Q22;Q22) Translocation cohort.

Asset / SponsorPhaseRating
Etoposide
Alice Mims
Phase 3BBB
Daunomycin
National Cancer Institute (NCI)
Phase 3BBB
Cytarabine
The First Affiliated Hospital of Soochow University
Phase 3BBB
Idarubicin
The First Affiliated Hospital of Soochow University
Phase 2BBB
2 (1H))-QUINOLINONE,6-(AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL)-4-(3-CHLOROPHENYL)-1-METHYL-,(+)-
National Cancer Institute (NCI)
Phase 2BBB

View all 50 →

Same molecule, other indications

Decitabine is also rated in:

disease related to hematopoietic stem cell transplantActive
BBB
Indicative · Phase 4
72 / 100
View asset →
acute myeloid leukemia with 11q23 abnormalitiesActive
BB
Indicative · Phase 3
69 / 100
View asset →
acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)Dormant
BB
Indicative · Phase 3
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →